Collectively, these results suggest that tumor cell biology underlying TGF-β signaling in an untreated prostate cancer setting is significantly associated with greater propensity to progress, manifesting clinically as a biochemical recurrence after RT. Here, TGFB1 is linked to prostate cancer.